Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2001

View Archived Issues

Health Canada approves Pantoloc for treatment of heartburn

Pharmacopeia and Mitsubishi-Tokyo establish new drug discovery collaboration

Medarex and Schering-Plough to develop human antibody therapeutics

Novel cardiovascular drugs sought by MediGene and Evotec BioSystems

NCI confirms antitumor activity of microalgae-derived Aquasearch compound

ACAT inhibitor originating in Japan advances through U.S. clinical trials

Next stage of clinical trials of oxaliplatin begins in Japan

Novartis, GeneData establish antimicrobial drug development alliance

Comprehensive review of Natrecor published in prestigious journal

Structure-based design of nonthiazolidinedione PPARgamma antagonists

Cinnamide-based LFA-1/ICAM-1 antagonists with improved properties presented at ACS meeting

Preclinical studies further explore antiangiogenic effects of squalamine

Biomira to pursue cancer vaccine development on its own

DepoCyte recommended for approval by CPMP

Potential of halofuginone in cancer therapy highlighted in AACR presentation

Valcyte approved by FDA for AIDS-related CMV

PNU-177684: discovery of a clinical antipsychotic candidate and selective D3 antagonist

Ortec seeks FDA approval to market wound-healing product in burn patients

Replacement of benzamidine with azaindole in Aventis series provides oral factor Xa inhibitors

Pharmos reports update on major products

ACS news: Sch-211803, a potent and highly selective M2 antagonist selected for clinical development

Timing of M-Vax administration crucial for survival and immunological outcomes

Improved paclitaxel derivatives in development at The Liposome Company

Novel aromatic amidine derivatives from Toa Eiyo useful as antithrombotic agents

Metabotropic glutamate receptor antagonists in development at NPS

Senju prepares new chymase inhibitor series for use in cardiovascular disorders

JNK inhibitors designed and tested at Signal

AstraZeneca presents newest series of PPARgamma activators in recent patent

Recently issued international patent describes compounds for neurodegenerative disorders

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...